Genmab Stock Nasdaq Copenhagen
Equities
DK0010272202
Biotechnology & Medical Research
Sales 2024 * | 19.68B 2.82B | Sales 2025 * | 23.49B 3.37B | Capitalization | 130B 18.69B |
---|---|---|---|---|---|
Net income 2024 * | 5.11B 733M | Net income 2025 * | 6.76B 969M | EV / Sales 2024 * | 5.23 x |
Net cash position 2024 * | 27.32B 3.92B | Net cash position 2025 * | 34.49B 4.95B | EV / Sales 2025 * | 4.08 x |
P/E ratio 2024 * |
25.8
x | P/E ratio 2025 * |
19.8
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 98.87% |
Latest transcript on Genmab
Managers | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | 63 | 98-12-31 | |
Anthony Pagano
DFI | Director of Finance/CFO | 46 | 06-12-31 |
Anthony Mancini
COO | Chief Operating Officer | 53 | 20-03-22 |
Members of the board | Title | Age | Since |
---|---|---|---|
Deirdre Connelly
CHM | Chairman | 63 | 16-12-31 |
Anders Pedersen
BRD | Director/Board Member | 73 | 03-10-31 |
Rolf K. Hoffmann
BRD | Director/Board Member | 63 | 15-12-31 |
1st Jan change | Capi. | |
---|---|---|
-0.49% | 103B | |
+3.31% | 96.73B | |
+1.66% | 21.31B | |
-16.16% | 21.21B | |
-41.41% | 16.37B | |
-22.87% | 13.68B | |
+6.32% | 13.44B | |
+21.46% | 10.98B | |
-21.14% | 8.56B |